Alexion Pharmaceuticals Stock News

Alexion Pharmaceuticals, Inc. (ALXN) CEO Ludwig Hantson on Q1 2020 Results - Earnings Call Transcript

Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Alexion earnings easily beat first-quarter estimates, but the biotech giant trimmed full-year targets. ALXN stock was not yet active early Wednesday.

Alexion Pharmaceuticals (NASDAQ: ALXN) shares are trading lower on Tuesday, after the company reported the purchase of Portola Pharma for $18 per share in cash.

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Alexion Pharmaceuticals pledged to buy Portola Pharmaceuticals on Tuesday in a deal that combines two blood disease-focused biotech companies. Alexion stock slipped, but Portola stock flew.

Shares of Portola Pharmaceuticals Inc. PTLA, +129.38% more than doubled in very active morning trading Tuesday, after the biopharmaceutical company focused on life-threatening blood-related disorders

Large-cap biopharma Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced a deal Tuesday to buy its small-cap peer Portola Pharmaceuticals Inc (NASDAQ: PTLA).

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

In value investing, investors pick stocks that are cheap but fundamentally sound. So, the chance of outperformance is high when the market moves higher.

In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $107.47, marking a -0.9% move from the previous day.